Balyasny Asset Management L.P. Has $175,000 Stock Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Balyasny Asset Management L.P. lessened its holdings in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 16.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 57,592 shares of the company’s stock after selling 11,070 shares during the quarter. Balyasny Asset Management L.P. owned approximately 0.08% of Zentalis Pharmaceuticals worth $175,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Voya Investment Management LLC increased its holdings in shares of Zentalis Pharmaceuticals by 14.1% during the 4th quarter. Voya Investment Management LLC now owns 57,017 shares of the company’s stock worth $173,000 after acquiring an additional 7,058 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of Zentalis Pharmaceuticals by 26.8% in the fourth quarter. Wells Fargo & Company MN now owns 34,609 shares of the company’s stock valued at $105,000 after purchasing an additional 7,305 shares during the period. Northern Trust Corp lifted its stake in shares of Zentalis Pharmaceuticals by 2.2% during the 4th quarter. Northern Trust Corp now owns 484,738 shares of the company’s stock worth $1,469,000 after buying an additional 10,513 shares during the last quarter. Federated Hermes Inc. boosted its holdings in shares of Zentalis Pharmaceuticals by 2.2% during the 4th quarter. Federated Hermes Inc. now owns 493,982 shares of the company’s stock worth $1,497,000 after buying an additional 10,644 shares during the period. Finally, Barclays PLC grew its stake in Zentalis Pharmaceuticals by 18.5% in the 3rd quarter. Barclays PLC now owns 75,395 shares of the company’s stock valued at $277,000 after buying an additional 11,748 shares during the last quarter.

Wall Street Analysts Forecast Growth

ZNTL has been the subject of a number of research analyst reports. UBS Group reduced their price objective on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a report on Tuesday, January 28th. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Zentalis Pharmaceuticals in a report on Thursday. Wedbush reaffirmed a “neutral” rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Thursday. Finally, Wells Fargo & Company lowered their price objective on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 30th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Zentalis Pharmaceuticals has a consensus rating of “Hold” and an average price target of $8.24.

Insiders Place Their Bets

In other news, Director Scott Dunseth Myers purchased 21,000 shares of Zentalis Pharmaceuticals stock in a transaction dated Wednesday, April 30th. The shares were bought at an average cost of $1.40 per share, for a total transaction of $29,400.00. Following the completion of the acquisition, the director now owns 281,192 shares in the company, valued at approximately $393,668.80. This trade represents a 8.07% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.90% of the company’s stock.

Zentalis Pharmaceuticals Stock Performance

ZNTL stock opened at $1.26 on Monday. Zentalis Pharmaceuticals, Inc. has a 12 month low of $1.01 and a 12 month high of $13.00. The stock has a market capitalization of $90.66 million, a P/E ratio of -0.51 and a beta of 1.81. The firm has a 50-day moving average price of $1.44 and a 200-day moving average price of $2.33.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, meeting analysts’ consensus estimates of ($0.67). As a group, equities analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.